SG10202000496XA - Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same - Google Patents

Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Info

Publication number
SG10202000496XA
SG10202000496XA SG10202000496XA SG10202000496XA SG10202000496XA SG 10202000496X A SG10202000496X A SG 10202000496XA SG 10202000496X A SG10202000496X A SG 10202000496XA SG 10202000496X A SG10202000496X A SG 10202000496XA SG 10202000496X A SG10202000496X A SG 10202000496XA
Authority
SG
Singapore
Prior art keywords
hepe
methods
same
pharmaceutical compositions
treating asthma
Prior art date
Application number
SG10202000496XA
Inventor
Mehar Manku
John Climax
Kevin Duffy
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of SG10202000496XA publication Critical patent/SG10202000496XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG10202000496XA 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same SG10202000496XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461926052P 2014-01-10 2014-01-10

Publications (1)

Publication Number Publication Date
SG10202000496XA true SG10202000496XA (en) 2020-03-30

Family

ID=53520398

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202000496XA SG10202000496XA (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
SG11201605601UA SG11201605601UA (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201605601UA SG11201605601UA (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Country Status (15)

Country Link
US (2) US20150196521A1 (en)
EP (1) EP3091959A4 (en)
JP (2) JP2017505809A (en)
KR (1) KR20160132372A (en)
CN (1) CN106029051A (en)
AU (1) AU2015204531B2 (en)
BR (1) BR112016015997A2 (en)
CA (1) CA2935986A1 (en)
IL (1) IL246623A0 (en)
MX (1) MX2016008953A (en)
PH (1) PH12016501371A1 (en)
RU (2) RU2685706C2 (en)
SG (2) SG10202000496XA (en)
WO (1) WO2015106215A2 (en)
ZA (1) ZA201605492B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568858B2 (en) 2012-05-10 2020-02-25 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
US10017453B2 (en) 2013-11-15 2018-07-10 Ds Biopharma Limited Pharmaceutically acceptable salts of fatty acids
CN112245420A (en) * 2015-07-21 2021-01-22 艾菲穆恩有限公司 Compositions comprising 15-HEPE for treating or preventing cancer and neurological diseases
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
US9855238B2 (en) * 2015-12-18 2018-01-02 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
CN111481550A (en) * 2020-05-14 2020-08-04 王兆霖 Pharmaceutical formulation containing tiotropium bromide and arformoterol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (en) * 1992-01-10 1993-07-27 Fujirebio Inc Antiinflammatory agent having immunoregulatory action
MXPA02007915A (en) * 2000-02-16 2005-06-20 Brigham & Womens Hospital Aspirin triggered lipid mediators.
US20020188024A1 (en) * 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20060160095A1 (en) * 2002-12-13 2006-07-20 Eirx Therapeutics Limited Survivin
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
HUE027076T2 (en) * 2005-03-16 2016-08-29 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US9238634B2 (en) * 2010-08-19 2016-01-19 The University Of Tokyo Anti-inflammatory metabolite derived from omega-3-type fatty acid
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
US10568858B2 (en) * 2012-05-10 2020-02-25 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (en) * 2014-12-02 2017-10-10 Afimmune Ltd COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM

Also Published As

Publication number Publication date
WO2015106215A3 (en) 2016-02-18
JP2017505809A (en) 2017-02-23
EP3091959A2 (en) 2016-11-16
CN106029051A (en) 2016-10-12
IL246623A0 (en) 2016-08-31
RU2685706C2 (en) 2019-04-23
JP2020002150A (en) 2020-01-09
RU2016132762A3 (en) 2018-09-20
SG11201605601UA (en) 2016-08-30
US20150196521A1 (en) 2015-07-16
KR20160132372A (en) 2016-11-18
US20160324820A1 (en) 2016-11-10
WO2015106215A2 (en) 2015-07-16
AU2015204531A1 (en) 2016-08-18
ZA201605492B (en) 2018-11-28
BR112016015997A2 (en) 2018-03-27
RU2019110980A (en) 2019-08-26
PH12016501371A1 (en) 2016-08-15
CA2935986A1 (en) 2015-07-16
EP3091959A4 (en) 2017-09-20
MX2016008953A (en) 2017-02-02
RU2016132762A (en) 2018-02-16
AU2015204531B2 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL251066B (en) Compositions and methods of use for treating metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
IL250744A0 (en) Method of producing palbociclib and pharmaceutical compositions comprising the same
IL259246A (en) Compositions of therapeutic substances, methods and uses thereof
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
EP3319976A4 (en) Compositions and methods for treating lung diseases and lung injury
ZA201605492B (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
HK1252567A1 (en) Substituted benzamides and methods of use thereof
IL265881A (en) Inhaler and methods of use thereof
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PL3154515T3 (en) Improvements to nasal compositions and method of use thereof
EP3131556A4 (en) Methods and compositions for treatment of copd diseases
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
EP3154616A4 (en) Methods and apparatus for treatment of respiratory disorders
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
GB201408387D0 (en) Treatment of respiratory disorders
IL259710A (en) Compositions and methods of treatment for mvid and related diseases
EP3142674A4 (en) Methods and compositions for treatment of macrophage-related disorders
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
HK1258056A1 (en) Therapeutic compounds and methods of use thereof
PT3233233T (en) Defoaming compositions comprising amphiphilic particles and methods of making and using the same
GB201511799D0 (en) Composition and methods of treatment
HK1258765A1 (en) Therapeutic compounds, compositions and methods of use thereof
EP3280406A4 (en) Compositions and methods for treatment of movement disorders